Premium
Efficacy, safety and toleration of fluconazole suppositories in the treatment of oral candidosis
Author(s) -
Andreas Plettenberg,
Albrecht Stoehr,
W Heise,
Frank Schlote,
E. Sarnow,
Marek Migdał
Publication year - 1999
Publication title -
mycoses
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.13
H-Index - 69
eISSN - 1439-0507
pISSN - 0933-7407
DOI - 10.1046/j.1439-0507.1999.00452.x
Subject(s) - medicine , suppository , fluconazole , clinical efficacy , surgery , antifungal , dermatology , pharmacology
An open multicentre, non‐comparative study was conducted in three countries to investigate the efficacy, safety and tolerance of fluconazole suppositories in the treatment of oropharyngeal candidosis. Patients received fluconazole 100 mg day −1 in the form of suppositories or capsules. Minimum duration of total treatment was 7 days, maximum total treatment duration was 14 days, and median duration of total treatment was 9.5 (7–14) days. After having received suppository‐based treatment for at least 5 days, patients could be switched to oral treatment. Eighty‐two male and 19 female patients with a mean age of 43 years were enrolled in the study. The median duration of suppository treatment was 8.9 (5–14) days. Patients were evaluated clinically and mycologically at regular intervals during and at the end of treatment. Seventy‐ nine of 101 patients enrolled in the study were considered efficacy‐evaluable. Clinical cure was achieved in 75 of 79 (95%) patients and improvement was seen in four of 79 (5%) at the end of therapy. At follow‐up after 1 month, clinical cure was observed in 48 of 63 (76%) patients. The results of this study demonstrates that the fluconazole suppository formulation is effective, safe and well tolerated.